Supernus Pharmaceuticals reported $178.88M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbott ABT:US USD 8.64B 245M
Aerie Pharmaceuticals AERI:US USD 62.8M 11.35M
Ani Pharmaceuticals ANIP:US USD 88.82M 2.05M
Aurora Cannabis Inc ACB:CN CAD 103.76M 571.03M
Bristol Myers Squibb BMY:US USD 8.75B 552M
Canopy Growth Corp WEED:CN CAD 277.53M 1.69B
Cara Therapeutics CARA:US USD 34.66M 7.18M
Corcept Therapeutics CORT:US USD 69.79M 2.16M
Eisai 4523:JP JPY 176.54B 283M
Eli Lilly And LLY:US USD 5.27B 12.8M
Endo International Ordinary Shares ENDP:US USD 1.18B 1.13B
Horizon Pharma HZNP:US USD 764.75M 23.1M
Lannett LCI:US USD 88.11M 64.04M
Marinus Pharmaceuticals MRNS:US USD 32.44M 6.12M
Pacira Pharmaceuticals PCRX:US USD 146.18M 8M
Perrigo Ordinary Shares PRGO:US USD 1.07B 71.2M
Pfizer PFE:US USD 13.23B 2.41B
Revance Therapeutics RVNC:US USD 106.5M 20.29M
Supernus Pharmaceuticals SUPN:US USD 178.88M 20.17M
Teva Pharmaceutical Industries TEVA:US USD 3.18B 1.56B
United Therapeutics UTHR:US USD 201.7M 63.4M
Xeris Pharmaceuticals Inc XERS:US USD 48.5M 4.28M